[Taufon and emoksipin in the combined treatment of sclerotic macular dystrophies].
The paper analyses results after complex treatment of 105 patients with sclerotic macular dystrophies. Taufon was added for treatment of early sclerotic macular dystrophies in 37 patients, emoxipine--of exudative sclerotic macular dystrophies in 23 patients. The treatment resulted in a more pronounced rise of visual functions, and stabilization of the dystrophic process in the retina ensued in earlier terms as compared with results achieved in 45 patients treated by traditional methods. Remote results of the treatment, followed up for two years in 70 patients, have shown that the usage of taufon and emoxipine allowed to achieve stabilization of visual functions in 76% of patients, while traditional methods of treatment stabilized visual functions in 61.6%. Differential prescription of the above preparations allowed to achieve the rise of visual functions and a more complete stabilization of the dystrophic process.
Shpak
N I
NI
Naritsyna
N I
NI
Konovalova
N V
NV
D000368:Aged; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008266:Macula Lutea / Q000473:pathology; D008268:Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010847:Picolines / Q000627:therapeutic use*; D012598:Sclerosis / Q000188:drug therapy / Q000503:physiopathology; D013654:Taurine / Q000627:therapeutic use*; D013997:Time Factors; D014792:Visual Acuity / Q000187:drug effects
D010847:Picolines; D013654:Taurine; C009820:6-methyl-2-ethyl-3-hydroxypyridine
Taufon i émoksipin v kompleksnom lechenii skleroticheskikh makulodistrofiĭ.